|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Licensing revenues | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expenses): | |||||
| Interest income | |||||
| Interest expense | |||||
| Change in fair value of warrant liability | |||||
| Total other income (expenses) | |||||
| Total other income (expenses) | |||||
| Net loss | |||||
| Other comprehensive loss: | |||||
| Unrealized loss on marketable securities, net | |||||
| Net comprehensive loss | |||||
| Dividend to Series B-1 preferred stockholders | |||||
| Dividends on Series B-1 Preferred Stock | |||||
| Net loss attributable to common stockholders | |||||
| Net loss per share attributable to common stockholders, basic (in Dollars per share) | |||||
| Net loss per share attributable to common stockholders, diluted (in Dollars per share) | |||||
| Weighted-average shares outstanding used in computing net loss per share, basic (in Shares) | |||||
| Weighted-average shares outstanding used in computing net loss per share, diluted (in Shares) | |||||
Loading...